TTX-030 + budigalimab + docetaxel

TTX-030 + budigalimab + docetaxel is a **combination regimen** under clinical investigation for advanced solid tumors, including metastatic pancreatic cancer. TTX-030 is a novel monoclonal antibody that inhibits CD39, an ectonucleotidase regulating the conversion of ATP to adenosine, thereby reducing immunosuppression in the tumor microenvironment and enhancing immune response[1][3][5]. Budigalimab is a humanized monoclonal antibody against programmed cell death protein 1 (PD-1), acting as an immune checkpoint inhibitor and boosting T cell mediated antitumor activity[2][3][4]. Docetaxel is a well-established cytotoxic chemotherapy agent from the taxane family that disrupts microtubule assembly, inhibiting cell division. Together, these agents are designed to synergize immunotherapeutic and cytotoxic mechanisms to improve clinical outcomes in patients with advanced cancers.